RESEARCH NEWS

Cell cycle (Georgetown, Tex.) · 2026-12-01

Stattic administration plays a protective role in a lipopolysaccharide-induced acute lung injury cell model.

Researchers studying NAD+ published a paper titled "Stattic administration plays a protective role in a lipopolysaccharide-induced acute lung injury cell model." in Cell cycle (Georgetown, Tex.) (2026 Dec). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

JPhys photonics · 2026-09-01

FLIMExplorer: interactive GUI for object-based visualization and analysis of fluorescence lifetime images.

Researchers studying NAD+ published a paper titled "FLIMExplorer: interactive GUI for object-based visualization and analysis of fluorescence lifetime images." in JPhys photonics (2026 Sep 1). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

European heart journal · 2026-08-07

A novel piece to the puzzle to gain holistic understanding on calcification in CAVD: a role for NAD+ metabolism.

Researchers studying NAD+ published a paper titled "A novel piece to the puzzle to gain holistic understanding on calcification in CAVD: a role for NAD+ metabolism." in European heart journal (2026 Aug 7). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Science advances · 2026-08-07

Renoprotective effects of tubular glucagon receptor activation mediated by V-ATPase.

Researchers studying MAZDUTIDE published a paper titled "Renoprotective effects of tubular glucagon receptor activation mediated by V-ATPase." in Science advances (2026 Aug 7). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: GLP1-GLUCAGON-DUAL-AGONIST-B

mBio · 2026-08-06

The anaerobic fungus Caecomyces churrovis produces H(2) via a non-bifurcating NADH-dependent enzyme complex.

Researchers studying NAD+ published a paper titled "The anaerobic fungus Caecomyces churrovis produces H(2) via a non-bifurcating NADH-dependent enzyme complex." in mBio (2026 Aug 6). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Neuron · 2026-08-06

Tau-induced mitochondrial reverse electron transport drives neurodegeneration.

Researchers studying NAD+ published a paper titled "Tau-induced mitochondrial reverse electron transport drives neurodegeneration." in Neuron (2026 Aug 6). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of the American Chemical Society · 2026-08-05

Carbon-Mediated Rechargeable Operation for Light-Driven Ammonia Production Using Quantum Dot-Azotobacter vinelandii Hybrids.

Researchers studying NAD+ published a paper titled "Carbon-Mediated Rechargeable Operation for Light-Driven Ammonia Production Using Quantum Dot-Azotobacter vinelandii Hybrids." in Journal of the American Chemical Society (2026 Aug 5). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Angewandte Chemie (International ed. in English) · 2026-08-05

J-Aggregated Macrocyclic Photocatalysts Enable Nitric Oxide (NO)-Enhanced Near-Infrared Photocatalytic Tumor Therapy.

Researchers studying NAD+ published a paper titled "J-Aggregated Macrocyclic Photocatalysts Enable Nitric Oxide (NO)-Enhanced Near-Infrared Photocatalytic Tumor Therapy." in Angewandte Chemie (International ed. in English) (2026 Aug 5). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

The FEBS journal · 2026-08-05

Common pathways and outliers in glucose catabolism across Trypanosomatidae.

Researchers studying NAD+ published a paper titled "Common pathways and outliers in glucose catabolism across Trypanosomatidae." in The FEBS journal (2026 Aug 5). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of the American Chemical Society · 2026-08-05

Reprogramming Glutathione-Binding Proteins into Artificial Photoenzymes by Engineered Glutathione-Type Cofactors.

Researchers studying NAD+ published a paper titled "Reprogramming Glutathione-Binding Proteins into Artificial Photoenzymes by Engineered Glutathione-Type Cofactors." in Journal of the American Chemical Society (2026 Aug 5). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Cell metabolism · 2026-08-05

Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD(+) to eradicate KRAS-driven AML.

Researchers studying NAD+ published a paper titled "Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD(+) to eradicate KRAS-driven AML." in Cell metabolism (2026 Aug 5). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of the American Chemical Society · 2026-08-05

Dynamic Coordination-Enabled Metal-Dependent Configurational Switching in a Covalent Organic Framework.

Researchers studying NAD+ published a paper titled "Dynamic Coordination-Enabled Metal-Dependent Configurational Switching in a Covalent Organic Framework." in Journal of the American Chemical Society (2026 Aug 5). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Molecular and cellular endocrinology · 2026-08-05

Bergamot (Citrus bergamia) Preserves Cardiac Structure and Function and Modulates Myocardial Redox and Metabolic Profiles in Diet-Induced Obesity.

Researchers studying NAD+ published a paper titled "Bergamot (Citrus bergamia) Preserves Cardiac Structure and Function and Modulates Myocardial Redox and Metabolic Profiles in Diet-Induced Obesity." in Molecular and cellular endocrinology (2026 Aug 5). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Clinical and experimental reproductive medicine · 2026-08-04

The impact of nicotinamide mononucleotide on ovarian health: A comprehensive literature review of preclinical evidence and therapeutic potential.

Researchers studying NAD+ published a paper titled "The impact of nicotinamide mononucleotide on ovarian health: A comprehensive literature review of preclinical evidence and therapeutic potential." in Clinical and experimental reproductive medicine (2026 Aug 4). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Brain, behavior, and immunity · 2026-08-03

Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats.

Researchers studying SS-31 published a paper titled "Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats." in Brain, behavior, and immunity (2026 Aug 3). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: SS-31

The Journal of cell biology · 2026-08-03

PARP1 hyperactivity stalls translation and triggers stress granule formation following DNA damage.

Researchers studying NAD+ published a paper titled "PARP1 hyperactivity stalls translation and triggers stress granule formation following DNA damage." in The Journal of cell biology (2026 Aug 3). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Molecular and cellular biochemistry · 2026-08-03

Liraglutide affects mitochondrial function and histone acetylation through the NQO1/SIRT3 pathway in diabetic kidney disease.

Researchers studying NAD+ published a paper titled "Liraglutide affects mitochondrial function and histone acetylation through the NQO1/SIRT3 pathway in diabetic kidney disease." in Molecular and cellular biochemistry (2026 Aug 3). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Human reproduction (Oxford, England) · 2026-08-03

Mitochondria-targeted therapeutic strategies in assisted reproduction: challenges and potential solutions.

Researchers studying NAD+ published a paper titled "Mitochondria-targeted therapeutic strategies in assisted reproduction: challenges and potential solutions." in Human reproduction (Oxford, England) (2026 Aug 3). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

ACS applied bio materials · 2026-08-03

Accelerating Biocatalysis in Interface-Regulated Nano-Bio Hybrid System via Increasing Substrate Accessibility.

Researchers studying NAD+ published a paper titled "Accelerating Biocatalysis in Interface-Regulated Nano-Bio Hybrid System via Increasing Substrate Accessibility." in ACS applied bio materials (2026 Aug 3). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Seminars in cell & developmental biology · 2026-08-03

Nutrient-sensing pathways in adult stem cells: Orchestrating homeostasis, aging, and disease.

Researchers studying NAD+ published a paper titled "Nutrient-sensing pathways in adult stem cells: Orchestrating homeostasis, aging, and disease." in Seminars in cell & developmental biology (2026 Aug 3). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Hypertension (Dallas, Tex. : 1979) · 2026-08-03

Roles of Sirtuin-1 in the Prevention of Intracranial Aneurysm Rupture in Mice.

Researchers studying NAD+ published a paper titled "Roles of Sirtuin-1 in the Prevention of Intracranial Aneurysm Rupture in Mice." in Hypertension (Dallas, Tex. : 1979) (2026 Aug 3). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Critical reviews in oncology/hematology · 2026-08-02

Decoding context-dependent sirtuin pharmacology in cancer: Metabolic-epigenetic switches and precision therapeutic targeting.

Researchers studying NAD+ published a paper titled "Decoding context-dependent sirtuin pharmacology in cancer: Metabolic-epigenetic switches and precision therapeutic targeting." in Critical reviews in oncology/hematology (2026 Aug 2). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Lancet (London, England) · 2026-07-30

Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Researchers studying AMYLIN RECEPTOR AGONIST published a paper titled "Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial." in Lancet (London, England) (2026 Jul 30). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: AMYLIN-RECEPTOR-AGONIST

Lancet (London, England) · 2026-07-30

Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Researchers studying AMYLIN RECEPTOR AGONIST published a paper titled "Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial." in Lancet (London, England) (2026 Jul 30). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: AMYLIN-RECEPTOR-AGONIST

GeroScience · 2026-07-30

Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial.

Researchers studying NAD+ published a paper titled "Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial." in GeroScience (2026 Jul 30). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Nature aging · 2026-07-30

The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming.

Researchers studying NAD+ published a paper titled "The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming." in Nature aging (2026 Jul 30). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Chemical communications (Cambridge, England) · 2026-07-30

Visualizing NO(2)(-)/NAD(P)H metabolic crosstalk in E. coli-infected bladder cancer via a dual-responsive probe.

Researchers studying NAD+ published a paper titled "Visualizing NO(2)(-)/NAD(P)H metabolic crosstalk in E. coli-infected bladder cancer via a dual-responsive probe." in Chemical communications (Cambridge, England) (2026 Jul 30). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Lancet (London, England) · 2026-07-30

A novel unimolecular GLP1 and amylin receptor agonist for glucose and weight control.

Researchers studying AMYLIN RECEPTOR AGONIST published a paper titled "A novel unimolecular GLP1 and amylin receptor agonist for glucose and weight control." in Lancet (London, England) (2026 Jul 30). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: AMYLIN-RECEPTOR-AGONIST

Journal of ophthalmology · 2026-07-29

Dysregulation of the Glycolytic Entry Gate and Survival Route by Advanced Lipoxidation End Products in Diabetes Mellitus.

Researchers studying NAD+ published a paper titled "Dysregulation of the Glycolytic Entry Gate and Survival Route by Advanced Lipoxidation End Products in Diabetes Mellitus." in Journal of ophthalmology (2026). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Chembiochem : a European journal of chemical biology · 2026-07-29

Synthesis, Characterization, and Fluorescence Application of Indole-Based Isofunctional NAD(+) Analogs.

Researchers studying NAD+ published a paper titled "Synthesis, Characterization, and Fluorescence Application of Indole-Based Isofunctional NAD(+) Analogs." in Chembiochem : a European journal of chemical biology (2026 Jul 29). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of agricultural and food chemistry · 2026-07-29

Stereoselective Reproductive and Intergenerational Toxicity of Prothioconazole in Female Zebrafish: Concurrent Ovarian Cytotoxicity and Endocrine Disruption.

Researchers studying NAD+ published a paper titled "Stereoselective Reproductive and Intergenerational Toxicity of Prothioconazole in Female Zebrafish: Concurrent Ovarian Cytotoxicity and Endocrine Disruption." in Journal of agricultural and food chemistry (2026 Jul 29). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Chembiochem : a European journal of chemical biology · 2026-07-29

Label-Free Monitoring of Cancer-Associated Fibroblast Activation Using NAD(P)H Fluorescence Lifetime Imaging.

Researchers studying NAD+ published a paper titled "Label-Free Monitoring of Cancer-Associated Fibroblast Activation Using NAD(P)H Fluorescence Lifetime Imaging." in Chembiochem : a European journal of chemical biology (2026 Jul 29). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

PloS one · 2026-07-29

Mapping the chaperonin TRiC/CCT interactome in mouse photoreceptors reveals functional significance for energy metabolism.

Researchers studying NAD+ published a paper titled "Mapping the chaperonin TRiC/CCT interactome in mouse photoreceptors reveals functional significance for energy metabolism." in PloS one (2026). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Cancer science · 2026-07-28

Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small-Cell Lung Cancer Models.

Researchers studying NAD+ published a paper titled "Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small-Cell Lung Cancer Models." in Cancer science (2026 Jul 28). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of clinical periodontology · 2026-07-28

Porphyromonas gingivalis Drives Trained Immunity via the Glycolysis-SIRT1 Axis to Aggravate Colitis.

Researchers studying NAD+ published a paper titled "Porphyromonas gingivalis Drives Trained Immunity via the Glycolysis-SIRT1 Axis to Aggravate Colitis." in Journal of clinical periodontology (2026 Jul 28). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of AOAC International · 2026-07-28

Enzymatic Determination of L-Malic Acid in Selected Foods and Beverages: AOAC Official Method 2025.03 First Action.

Researchers studying NAD+ published a paper titled "Enzymatic Determination of L-Malic Acid in Selected Foods and Beverages: AOAC Official Method 2025.03 First Action." in Journal of AOAC International (2026 Jul 28). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Inflammopharmacology · 2026-07-28

Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination.

Researchers studying NAD+ published a paper titled "Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination." in Inflammopharmacology (2026 Jul 28). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Proceedings of the National Academy of Sciences of the United States of America · 2026-07-28

Peroxisomal ether lipid synthesis regulates cortical neurogenesis and maintains mitochondrial energy homeostasis in radial glial cells.

Researchers studying NAD+ published a paper titled "Peroxisomal ether lipid synthesis regulates cortical neurogenesis and maintains mitochondrial energy homeostasis in radial glial cells." in Proceedings of the National Academy of Sciences of the United States of America (2026 Jul 28). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Bioresource technology · 2026-07-26

Fatty acid decarboxylases for sustainable linear α-olefin production: mechanisms, engineering strategies, and applications.

Researchers studying NAD+ published a paper titled "Fatty acid decarboxylases for sustainable linear α-olefin production: mechanisms, engineering strategies, and applications." in Bioresource technology (2026 Jul 26). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

International journal of biological macromolecules · 2026-07-26

Engineering alanine dehydrogenase to favor nicotinamide cytosine dinucleotide for formate-driven alanine synthesis.

Researchers studying NAD+ published a paper titled "Engineering alanine dehydrogenase to favor nicotinamide cytosine dinucleotide for formate-driven alanine synthesis." in International journal of biological macromolecules (2026 Jul 26). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Metabolism: clinical and experimental · 2026-07-26

Metabolic control of renal cell fate in kidney disease: nutrient rewiring, senescence and fibrosis.

Researchers studying NAD+ published a paper titled "Metabolic control of renal cell fate in kidney disease: nutrient rewiring, senescence and fibrosis." in Metabolism: clinical and experimental (2026 Jul 26). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Chemico-biological interactions · 2026-07-25

High susceptibility of mouse hepatic Cyp2a to the inactivation by oral imperatorin: isoform sensitivity and tissue specificity.

Researchers studying NAD+ published a paper titled "High susceptibility of mouse hepatic Cyp2a to the inactivation by oral imperatorin: isoform sensitivity and tissue specificity." in Chemico-biological interactions (2026 Jul 25). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Cancer letters · 2026-07-25

SARM1-Dependent Antimetabolic Cancer Therapy.

Researchers studying NAD+ published a paper titled "SARM1-Dependent Antimetabolic Cancer Therapy." in Cancer letters (2026 Jul 25). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Chemico-biological interactions · 2026-07-25

Lipophilicity and alkyl chain length govern pyridine quaternary ammonium disinfectants as gonadal 3β-hydroxysteroid dehydrogenase inhibitors: Implications for endocrine disruption.

Researchers studying NAD+ published a paper titled "Lipophilicity and alkyl chain length govern pyridine quaternary ammonium disinfectants as gonadal 3β-hydroxysteroid dehydrogenase inhibitors: Implications for endocrine disruption." in Chemico-biological interactions (2026 Jul 25). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Cell reports · 2026-07-25

Tracing NAD(+) metabolism uncovers adaptive coordination between host and microbiome during colitis.

Researchers studying NAD+ published a paper titled "Tracing NAD(+) metabolism uncovers adaptive coordination between host and microbiome during colitis." in Cell reports (2026 Jul 25). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Functional plant biology : FPB · 2026-07-24

The role of redox state in regulating plant secondary metabolism under stress.

Researchers studying NAD+ published a paper titled "The role of redox state in regulating plant secondary metabolism under stress." in Functional plant biology : FPB (2026 Jul 24). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Autophagy · 2026-07-24

NAD(+) modulates REST isoform expression and its downstream mitophagy in Alzheimer's disease.

Researchers studying NAD+ published a paper titled "NAD(+) modulates REST isoform expression and its downstream mitophagy in Alzheimer's disease." in Autophagy (2026 Jul 24). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of radiation research · 2026-07-24

Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.

Researchers studying SS-31 published a paper titled "Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence." in Journal of radiation research (2026 Jul 24). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: SS-31

Antimicrobial agents and chemotherapy · 2026-07-23

Using a liver-on-chip model to evaluate the effects of vancomycin and daptomycin on host immunometabolism and clearance of intracellular reservoirs of Staphylococcus aureus during bacteremia.

Researchers studying NAD+ published a paper titled "Using a liver-on-chip model to evaluate the effects of vancomycin and daptomycin on host immunometabolism and clearance of intracellular reservoirs of Staphylococcus aureus during bacteremia." in Antimicrobial agents and chemotherapy (2026 Jul 23). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Molecular biology reports · 2026-07-23

NAD⁺ biology and supplementation: From mechanisms to clinical perspectives.

Researchers studying NAD+ published a paper titled "NAD⁺ biology and supplementation: From mechanisms to clinical perspectives." in Molecular biology reports (2026 Jul 23). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Biochemical and biophysical research communications · 2026-07-23

NMN mitigates high-altitude hypoxia-induced cognitive impairment by inhibiting microglial ferroptosis.

Researchers studying NAD+ published a paper titled "NMN mitigates high-altitude hypoxia-induced cognitive impairment by inhibiting microglial ferroptosis." in Biochemical and biophysical research communications (2026 Jul 23). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

European journal of pharmacology · 2026-07-23

S14G-humanin (HNG) ameliorates diabetic nephropathy tubular injury by inhibiting Z-DNA/ZBP1-mediated necroptosis.

Researchers studying HUMANIN published a paper titled "S14G-humanin (HNG) ameliorates diabetic nephropathy tubular injury by inhibiting Z-DNA/ZBP1-mediated necroptosis." in European journal of pharmacology (2026 Jul 23). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: HUMANIN

Journal of medicinal chemistry · 2026-07-23

Discovery of a Potent NAMPT-Targeting PROTAC for the Suppression of Triple-Negative Breast Cancer via Macrophage Reprogramming.

Researchers studying NAD+ published a paper titled "Discovery of a Potent NAMPT-Targeting PROTAC for the Suppression of Triple-Negative Breast Cancer via Macrophage Reprogramming." in Journal of medicinal chemistry (2026 Jul 23). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Molecular aspects of medicine · 2026-07-23

Feeding the epigenome: EZH2 as a metabolic integrator of cell fate in development and cancer.

Researchers studying NAD+ published a paper titled "Feeding the epigenome: EZH2 as a metabolic integrator of cell fate in development and cancer." in Molecular aspects of medicine (2026 Jul 23). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Physiological research · 2026-07-22

Effects of Different Duration of High-Fat Feeding on the NAD+/Sirtuins/PGC1alpha Axis in Relation to Oxidative Stress in Rat Skeletal Muscle.

Researchers studying NAD+ published a paper titled "Effects of Different Duration of High-Fat Feeding on the NAD+/Sirtuins/PGC1alpha Axis in Relation to Oxidative Stress in Rat Skeletal Muscle." in Physiological research (2026 Jul 22). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Molecular biomedicine · 2026-07-22

SelO-mediated NAD(+) hydrolysis safeguards mitochondrial homeostasis.

Researchers studying NAD+ published a paper titled "SelO-mediated NAD(+) hydrolysis safeguards mitochondrial homeostasis." in Molecular biomedicine (2026 Jul 22). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

MedComm · 2026-07-22

SIRT Family: Biological Functions and Therapeutic Targets.

Researchers studying NAD+ published a paper titled "SIRT Family: Biological Functions and Therapeutic Targets." in MedComm (2026 Aug). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Blood cancer discovery · 2026-07-21

The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells.

Researchers studying NAD+ published a paper titled "The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells." in Blood cancer discovery (2026 Jul 21). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Scientific reports · 2026-07-21

First report on the chemical profile and antioxidant activity of Moroccan Crithmum maritimum essential oils.

Researchers studying NAD+ published a paper titled "First report on the chemical profile and antioxidant activity of Moroccan Crithmum maritimum essential oils." in Scientific reports (2026 Jul 21). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Comparative biochemistry and physiology. Toxicology & pharmacology : CBP · 2026-07-21

The SIRT gene family protects against oxidative stress and mitochondrial dynamic dysfunction induced by polystyrene nanoplastics in the ovaries of zebrafish (Danio rerio).

Researchers studying NAD+ published a paper titled "The SIRT gene family protects against oxidative stress and mitochondrial dynamic dysfunction induced by polystyrene nanoplastics in the ovaries of zebrafish (Danio rerio)." in Comparative biochemistry and physiology. Toxicology & pharmacology : CBP (2026 Jul 21). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS